XML 36 R21.htm IDEA: XBRL DOCUMENT
v3.25.3

Earnings Per Common Share | 9 Months Ended
--- | ---
Sep. 30, 2025
Earnings Per Share [Abstract] |
Earnings Per Common Share | Earnings Per Common Share Basic income (loss) per common share (“EPS”) is computed based on the weighted average number of common shares outstanding. Diluted income (loss) per common share is computed based on the weighted average number of common shares outstanding plus the impact of forward equity sales agreements using the treasury stock method, common shares issuable from the assumed conversion of DownREIT units, stock options, certain performance restricted stock units, OP Units, and unvested restricted stock units. Only those instruments having a dilutive impact on the Company’s basic income (loss) per share are included in diluted income (loss) per share during the periods presented. Certain restricted stock units are considered participating securities, because dividend payments are not forfeited even if the underlying award does not vest, and require use of the two-class method when computing basic and diluted earnings per share. The Company considers the potential dilution resulting from forward agreements under its ATM Program to the calculation of earnings per share. At inception, the agreements do not have an effect on the computation of basic EPS as no shares are delivered until settlement. However, the Company uses the treasury stock method to calculate the dilution, if any, resulting from the forward sales agreements during the period of time prior to settlement. Refer to Note 12 for a discussion of the sale of shares under and settlement of forward sales agreements, of which there were none during the three and nine months ended September 30, 2025 and 2024. The following table illustrates the computation of basic and diluted earnings per share (in thousands, except per share amounts):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Numerator - Basic |  |  |  |  |  |  |
Net income (loss) | $ | (109,848) |  |  | $ | 92,738 |  |  | $ | (20,765) |  |  | $ | 256,631 |
Noncontrolling interests’ share in earnings | (7,274) |  |  | (6,866) |  |  | (21,856) |  |  | (18,036) |
Net income (loss) attributable to Healthpeak Properties, Inc. | (117,122) |  |  | 85,872 |  |  | (42,621) |  |  | 238,595 |
Less: Participating securities’ share in earnings | (134) |  |  | (197) |  |  | (714) |  |  | (610) |
Net income (loss) applicable to common shares | $ | (117,256) |  |  | $ | 85,675 |  |  | $ | (43,335) |  |  | $ | 237,985 |
Numerator - Dilutive |  |  |  |  |  |  |
Net income (loss) applicable to common shares | $ | (117,256) |  |  | $ | 85,675 |  |  | $ | (43,335) |  |  | $ | 237,985 |
Add: distributions on dilutive convertible units and other | — |  |  | 47 |  |  | — |  |  | 72 |
Dilutive net income (loss) available to common shares | $ | (117,256) |  |  | $ | 85,722 |  |  | $ | (43,335) |  |  | $ | 238,057 |
Denominator |  |  |  |  |  |  |
Basic weighted average shares outstanding | 694,930 |  |  | 699,349 |  |  | 696,380 |  |  | 667,536 |
Dilutive potential common shares - equity awards(1) | — |  |  | 137 |  |  | — |  |  | 150 |
Dilutive potential common shares - OP Units(2) | — |  |  | 660 |  |  | — |  |  | 410 |
Diluted weighted average common shares | 694,930 |  |  | 700,146 |  |  | 696,380 |  |  | 668,096 |
Earnings (loss) per common share |  |  |  |  |  |  |
Basic | $ | (0.17) |  |  | $ | 0.12 |  |  | $ | (0.06) |  |  | $ | 0.36 |
Diluted | $ | (0.17) |  |  | $ | 0.12 |  |  | $ | (0.06) |  |  | $ | 0.36 |
_______________________________________ (1)For each of the three and nine months ended September 30, 2025, the 1 million outstanding equity awards (restricted stock units and stock options) were anti-dilutive. For each of the three and nine months ended September 30, 2024, represents the dilutive impact of 1 million outstanding equity awards (restricted stock units and stock options). (2)For each of the three and nine months ended September 30, 2025, all 4 million outstanding OP Units were anti-dilutive. For each of the three and nine months ended September 30, 2024, represents the dilutive impact of 3 million outstanding OP Units. For each of the three and nine months ended September 30, 2025, all 13 million shares issuable upon conversion of DownREIT units were not included because they were anti-dilutive. For each of the three and nine months ended September 30, 2024, all 14 million shares issuable upon conversion of DownREIT units were not included because they were anti-dilutive.

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration